【藥品性質提示】 #高警訊藥品

Prevention of postpartum hemorrhage

Oxytocic Agent
Binds oxytocin receptors located in uterine smooth muscle producing rhythmic uterine contractions characteristic to deliver, as well as increasing both the frequency of existing contractions and uterine tone. Enhances uterine involution early in postpartum.

Onset of action: 1.2 ± 0.5 minutes
Duration: ~60 minutes
Half-life elimination: ~40 minutes
Excretion: Urine (<1%, as unchanged drug)

1. Hypersensitivity to carbetocin, oxytocin, or any component of the formulation
2. Administration prior to delivery of infant for any reason (including elective or medical induction of labor)
3. Serious cardiovascular disorders
4. Use in children

Use in pregnancy prior to delivery is contraindicated. Carbetocin induced contractions are of a longer duration than those observed with oxytocin and are not stopped by discontinuation of therapy. Improper use during pregnancy may produce symptoms similar to those observed with oxytocin overdosage (eg, hyperstimulation of uterus, uterine rupture).

Carbetocin is present in breast milk.

Flushing, hypotension, headache, pruritus, abdominal pain, nausea, vomiting, tremor, feeling of warmth

IV: 100 mcg (single dose only)

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).